Cannabinoid Receptor Agonists

Compounds that interact with and stimulate the activity of CANNABINOID RECEPTORS.

Also Known As:

Cannabinoid Agonists; Cannabinoid Receptor Activators; Activators, Cannabinoid Receptor; Agonist, Cannabinoid; Agonist, Cannabinoid Receptor; Agonists, Cannabinoid; Agonists, Cannabinoid Receptor; Receptor Activators, Cannabinoid; Receptor Agonist, Cannabinoid; Receptor Agonists, Cannabinoid; Cannabinoid Agonist; Cannabinoid Receptor Agonist

Networked: 461 relevant articles (37 outcomes, 81 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Chemical Actions and Uses
- Pharmacologic Actions: 160
  - Molecular Mechanisms of Pharmacological Action: 24
    - Neurotransmitter Agents: 13181
      - Cannabinoid Receptor Modulators: 2
        Cannabinoid Receptor Agonists: 461
  - Physiological Effects of Drugs: 1
    - Hormones, Hormone Substitutes, and Hormone Antagonists
      - Hormones: 80400
        Cannabinoid Receptor Modulators: 2
        Cannabinoid Receptor Agonists: 461

Experts

1.	Mitchell, Vanessa A: 7 articles (01/2016 - 07/2005)
2.	Vaughan, Christopher W: 7 articles (01/2016 - 07/2005)
3.	Simone, Donald A: 7 articles (02/2012 - 05/2003)
4.	Hohmann, Andrea G: 6 articles (10/2021 - 02/2004)
5.	France, Charles P: 6 articles (08/2018 - 12/2012)
6.	Cravatt, Benjamin F: 6 articles (06/2018 - 04/2004)
7.	Martín, María Isabel: 6 articles (02/2014 - 11/2005)
8.	Lichtman, Aron H: 5 articles (06/2018 - 07/2010)
9.	Wiley, Jenny L: 5 articles (01/2018 - 01/2011)
10.	Mechoulam, Raphael: 5 articles (01/2016 - 02/2002)

Related Diseases

1.	Neuralgia (Stump Neuralgia) 01/01/2016 - "Thus, dual FAAH/MAGL inhibition may have greater potential in alleviating neuropathic pain, compared with selective FAAH and MAGL inhibitors, or cannabinoid receptor agonists." 01/01/2016 - "Cannabinoid receptor agonists have good efficacy in animal models of neuropathic pain; they have a poor therapeutic window. " 05/01/2015 - "Cannabinoid receptor agonists are moderately effective at reducing neuropathic pain but are limited by psychoactivity. " 07/26/2012 - "Cannabinoid receptor agonists have gained attention as potential therapeutic targets of inflammatory and neuropathic pain. " 11/01/2010 - "A peripherally restricted cannabinoid receptor agonist produces robust anti-nociceptive effects in rodent models of inflammatory and neuropathic pain."
2.	Hyperalgesia 12/05/2005 - "The aim of the present study was to investigate the effects of cannabinoid agonists on established inflammatory hyperalgesia. " 04/01/2013 - "Cannabinoid agonists alleviated mechanical allodynia. " 01/01/2011 - "Systemic treatment with cannabinoid agonists reduced mechanical allodynia on both the 5(th) and 30(th) days after surgery, but the greatest results were observed by using central routes of administration, especially at the 30(th) day. " 09/01/2009 - "Direct-acting cannabinoid receptor agonists are well known to reduce hyperalgesic responses and allodynia after nerve injury, although their psychoactive side effects have damped enthusiasm for their therapeutic development. " 10/01/2003 - "Cannabinoid receptor agonists inhibit inflammatory hyperalgesia in animal models. "
3.	Pain (Aches) 12/01/2021 - "Cannabinoid receptor agonists resulted in statistically significant improvement in locomotor function in 9 out of 10 studies and pain outcomes in 6 out of 6 studies. " 01/01/2011 - "Our results indicate a relevant role for cannabinoid agonists in BPA, reinforcing their potential therapeutic relevance for the management of chronic pain states." 07/01/2006 - "Further double-blind placebo-controlled clinical trials are needed to evaluate the potential therapeutic effectiveness of various cannabinoid agonists-based medications for controlling different types of pain." 02/01/2006 - "Studies of cannabinoid agonists for treatment of pain were selected and were not limited by pain type or etiology. " 05/01/2021 - "Consequently, there is increasing interest in developing cannabinoid receptor agonists for treating pain. "
4.	Cognitive Dysfunction 03/01/2005 - "Previous reports have described a cognitive impairment effect of cannabinoid agonists, or facilitation by antagonists. " 01/01/2018 - "The potential protective effects of cannabinoid receptor agonist WIN55,212-2 on cognitive dysfunction is associated with the suppression of autophagy and inflammation in an experimental model of vascular dementia." 12/01/2004 - "These results suggest that CB1Rs mediate the attentional performance impairments caused by acute administration of cannabinoid agonists and begin to unravel the possible contribution of cannabinoid systems to the pathophysiological substrates of cognitive dysfunction in schizophrenia." 10/15/2016 - "The present study further investigated the protective effects of cannabinoid receptor agonist WIN55,212-2 (WIN) and fatty acid amide hydrolase (FAAH) inhibitor URB597 (URB) on chronic cerebral hypoperfusion (CCH)-induced cognitive impairment in rats. " 10/15/2016 - "Cannabinoid receptor agonist WIN55,212-2 and fatty acid amide hydrolase inhibitor URB597 may protect against cognitive impairment in rats of chronic cerebral hypoperfusion via PI3K/AKT signaling."
5.	Chronic Pain 08/15/2020 - "Exogenous cannabinoid receptor agonists are clinically effective for treating chronic pain but frequently cause side effects in the central nervous system. " 09/10/2015 - "Sustained administration of cannabinoid agonists acting on neuronal CB1 receptors (CB1Rs) are proposed for treating spasticity and chronic pain. " 07/01/2006 - "In this review, we will examine promising indications of cannabinoid receptor agonists to alleviate acute and chronic pain episodes. " 11/01/2008 - "Animal models of chronic pain conditions resulting from peripheral inflammatory reactions or nerve injuries are responsive to treatment with cannabinoid agonists. " 01/01/1999 - "A sizable body of previous work showed that cannabinoid agonists suppress pain behavior in a variety of models of acute and chronic pain. "

Related Drugs and Biologics

1.	(3R)- ((2,3- dihydro- 5- methyl- 3- ((4- morpholinyl)methyl)pyrrolo- (1,2,3- de)- 1,4- benzoxazin- 6- yl)(1- naphthalenyl))methanone (WIN 55,212)
2.	cyclohexyl carbamic acid 3'-carbamoylbiphenyl-3-yl ester (URB597)
3.	fatty-acid amide hydrolase (fatty acid amide hydrolase)
4.	CB1 Cannabinoid Receptor (CB1 Receptor)
5.	Analgesics (Analgesic Drugs)
6.	nabilone (Cesamet)
7.	N- (7- (1- hydroxyethyl)- 3- (4- isopropylphenyl)- 4,6- dimethyl- 2,3- dihydro- 1- benzofuran- 5- yl)- 3,3- dimethylbutanamide
8.	Paclitaxel (Taxol)
9.	Cannabinoids
10.	HU 211 (HU 210)

Related Therapies and Procedures

1.	Therapeutics
2.	Analgesia
3.	Ligation
4.	Drug Therapy (Chemotherapy)
5.	Self Medication